Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Hank

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|May 25, 1989
Tumor-infiltrating lymphocytes and interleukin-2 in melanomasP M Sondel, J A Sosman, J A Hank, et al.
Tumori|October 31, 1991
In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patientsC Gambacorti-Passerini, J A Hank, A Borchert, et al.
The Journal of Experimental Medicine|August 1, 1980
Cloned primed-lymphocyte-test reagents in the dissection of HLA-DH Inouye, J A Hank, X Chardonnens, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 1994
Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogsS C Helfand, S A Soergel, P S MacWilliams, et al.
Human Immunology|July 1, 1987
Differential antigen presentation by heat-treated peripheral blood mononuclear cells and Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL): heated EBV-LCL present alloantigen and soluble antigen but are deficient in the stimulation of autologous EBV-LCL primed T cellsR B Mandell, J A Hank, B P Chen, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivoJ A Hank, G Weil-Hillman, J E Surfus, et al.
Cancer Biotherapy|January 1, 1994
Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitroS C Helfand, S A Soergel, J F Modiano, et al.
Bulletin of the New York Academy of Medicine|January 1, 1989
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatmentS D Voss, G Weil-Hillman, J A Hank, et al.
Clinical and Diagnostic Laboratory Immunology|March 6, 1999
Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteinsJ Gan, K Kendra, M Ricci, et al.
Diagnostic Immunology|January 1, 1985
HLA typing and karyotyping of limited numbers of lymphocytes is facilitated by in vitro expansion with TCGFJ L Blank, J A Hank, J Molenda, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|May 25, 1989
Tumor-infiltrating lymphocytes and interleukin-2 in melanomasP M Sondel, J A Sosman, J A Hank, et al.
Tumori|October 31, 1991
In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patientsC Gambacorti-Passerini, J A Hank, A Borchert, et al.
The Journal of Experimental Medicine|August 1, 1980
Cloned primed-lymphocyte-test reagents in the dissection of HLA-DH Inouye, J A Hank, X Chardonnens, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 1994
Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogsS C Helfand, S A Soergel, P S MacWilliams, et al.
Human Immunology|July 1, 1987
Differential antigen presentation by heat-treated peripheral blood mononuclear cells and Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL): heated EBV-LCL present alloantigen and soluble antigen but are deficient in the stimulation of autologous EBV-LCL primed T cellsR B Mandell, J A Hank, B P Chen, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivoJ A Hank, G Weil-Hillman, J E Surfus, et al.
Cancer Biotherapy|January 1, 1994
Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitroS C Helfand, S A Soergel, J F Modiano, et al.
Bulletin of the New York Academy of Medicine|January 1, 1989
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatmentS D Voss, G Weil-Hillman, J A Hank, et al.
Clinical and Diagnostic Laboratory Immunology|March 6, 1999
Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteinsJ Gan, K Kendra, M Ricci, et al.
Diagnostic Immunology|January 1, 1985
HLA typing and karyotyping of limited numbers of lymphocytes is facilitated by in vitro expansion with TCGFJ L Blank, J A Hank, J Molenda, et al.
Pageof 10